Subsequent Breast Cancer Risk Higher for Child Cancer Survivors Receiving Doxorubicin
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 19, 2023 -- For female survivors of childhood cancer, the risk for subsequent breast cancer (SBC) is more than twofold higher for those who receive a cumulative dose of 200 mg/m² or more of doxorubicin compared with those who never receive doxorubicin, according to a study published online Sept. 11 in Nature Medicine.
Yuehan Wang, from the Princess Máxima Center for Pediatric Oncology in Utrecht, Netherlands, and colleagues pooled individual patient data for 17,903 female childhood cancer survivors from six studies, of whom 4.4 percent developed an SBC, to assess associations with individual anthracycline agents and any interactions with chest radiotherapy.
The researchers observed a dose-dependent increased risk for SBC for doxorubicin (hazard ratio, 1.24 per 100 mg/m²), with more than a twofold increase for those treated with 200 mg/m² or more cumulative doxorubicin versus no doxorubicin (hazard ratios, 2.50, 2.33, and 2.78 for 200 to 299, 300 to 399, and ≥400 mg/m², respectively). Hazard ratios per 100 mg/m² doxorubicin were 1.11 and 1.26 for patients treated with or without chest irradiation, respectively. Increased SBC risk was also seen in association with epirubicin (yes/no: hazard ratio, 3.25). The associations for daunorubicin were not statistically significant.
"Our findings support that it may be reasonable to initiate early breast cancer screening in female childhood cancer survivors who have received ≥200 mg/m² cumulative doxorubicin dose," the authors write. "We believe that the results of our study should be considered in updates of the SBC surveillance guidelines for survivors and can inform future treatment protocols for newly diagnosed childhood cancer patients."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Resistance Exercise Boosts Outcomes After Early-Stage Breast Cancer Surgery
FRIDAY, June 7, 2024 -- Early resistance exercise following surgery for early-stage breast cancer improves shoulder range of motion (ROM) and strength at one month and six months...
ASCO: Germline Variation Does Not Predict Taxane-Induced Peripheral Neuropathy
FRIDAY, June 7, 2024 -- Germline variation does not predict the risk of taxane-induced peripheral neuropathy (TIPN) in Black women receiving paclitaxel (once weekly) or docetaxel...
Pandemic Had Temporary Negative Effect on Breast Cancer Screening
THURSDAY, May 30, 2024 -- The COVID-19 pandemic had a transient negative effect on breast cancer screening overall and a prolonged negative effect on follow-up screening...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.